2011
DOI: 10.3233/jad-2011-110626
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Increased levels of isoaspartyl residues (isoAsp) have previously been found in proteins of Alzheimer's disease (AD) brains and in blood proteins of patients suffering from uremia, the disease sharing common pathological features with AD. One can hypothesize that higher levels of isoAsp should be present in blood proteins of AD patients. Also, because of higher AD prevalence in females, they can be expected to have higher level of isoAsp than males. Here we modified our recently developed proteome-wide isoAsp … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
35
0

Year Published

2012
2012
2016
2016

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 24 publications
(39 citation statements)
references
References 40 publications
(38 reference statements)
4
35
0
Order By: Relevance
“…ETD analysis shows that for doubly charged peptide ions, supplemental activation is essential to obtain the diagnostic c + 57 or z − 57 ions needed to differentiate aspartic and isoaspartic acids from deamidated, digested peptide samples [44]. This method has been applied to a large scale analysis of blood samples from Alzheimer disease patients [48]. …”
Section: Analysis Of Ptms By Etdmentioning
confidence: 99%
“…ETD analysis shows that for doubly charged peptide ions, supplemental activation is essential to obtain the diagnostic c + 57 or z − 57 ions needed to differentiate aspartic and isoaspartic acids from deamidated, digested peptide samples [44]. This method has been applied to a large scale analysis of blood samples from Alzheimer disease patients [48]. …”
Section: Analysis Of Ptms By Etdmentioning
confidence: 99%
“…2527 In the previous study of blood plasma proteins, we only investigated isomerization-produced isoAsp because of the low level of isoAsp in human blood. 16 In the present study, higher levels of isoAsp are expected in the PIMT-KO mouse brain cells, 4, 5 which reduces the concern over in vitro deamidation. Even if some deamidation occurs during sample preparation, a higher level of isoAsp residues at a particular site in a PIMT-KO protein relative to its WT counterpart will indicate that this isoAsp is a physiological substrate of PIMT.…”
Section: Introductionmentioning
confidence: 51%
“…These included requirements for adjacent c/z • fragments, specific losses from the reduced species, and exclusion of unreliable identifications based on the shape of the chromatographic peak (thereby removing n = 247 putative false identifications [53% of the total] detected during their initial proteome‐wide analyses). Later the same research group applied this optimized proteomic strategy to identify significantly higher levels of isoAsp residues in the pooled plasma of patients with AD ( P = 0.03) (Yang et al, ). The authors were then able to validate this finding by conducting individual analyses of 96 separate patient samples (with a combined P ‐value ≈ 0.01), thus strongly suggesting that high levels of isoAsp are associated with the pathology of AD.…”
Section: Recent Technological Advances In the Study Of Protein Deamidmentioning
confidence: 99%